Table 1.
In vitro inhibitory effects of compounds 2a, 3a–j, 4a–i, and CA-4 against the proliferation of murine leukemia (L1210), murine mammary carcinoma (FM3A), human T-lymphocyte (Molt/4 and CEM), and human cervix carcinoma (HeLa) cells.
| Compd | L1210 | FM3A/0 | IC50 [nm][a] Molt4/C8 | CEM/0 | HeLa |
|---|---|---|---|---|---|
| 3a | 6700 ± 600 | 9200 ± 800 | ND | 5400 ± 1200 | 2200 ± 600 |
| 3b | > 10 000 | > 10 000 | > 10 000 | > 10 000 | > 10 000 |
| 3c | 2500 ± 100 | 3600 ± 150 | ND | 2400 ± 400 | 5500 ± 530 |
| 3d | > 10 000 | > 10 000 | > 10 000 | > 10000 | 7500±200 |
| 3e | > 10 000 | > 10 000 | > 10 000 | > 10 000 | > 10 000 |
| 3f | > 10 000 | > 10 000 | > 10 000 | > 10 000 | > 10 000 |
| 3g | 73 ± 24 | 73 ± 2 | 66 ± 6.7 | 59 ± 4.1 | 42 ± 3.8 |
| 3h | 19 ± 2 | 24 ± 6 | 22 ± 4 | 22 ± 5 | 16 ± 1 |
| 3i | 600 ± 90 | 560 ± 90 | 870 ± 20 | 450 ± 10 | 370 ± 30 |
| 3j | 67 ± 4 | 140 ± 13 | 360 ± 20 | 120 ± 10 | 490 ± 54 |
| 4a | 78 ± 2.8 | 200 ± 90 | ND | 110 ± 20 | 1000 ± 80 |
| 4b | 150 ± 8 | 320 ± 30 | 230 ± 1 | 390 ± 30 | 1100 ± 90 |
| 4c | 320 ± 17 | 520 ± 29 | ND | 310 ± 80 | 430 ± 90 |
| 4d | 420 ± 90 | 1200 ± 90 | ND | 600 ± 37 | 1200 ± 80 |
| 4e | 800 ± 51 | 780 ± 62 | 1100 ± 90 | 970 ± 55 | 1000 ± 100 |
| 4f | 1200 ± 40 | 5900 ± 380 | ND | 3200 ± 240 | 5900 ± 900 |
| 4g | 430 ± 23 | 960 ± 78 | ND | 340 ± 20 | 1000 ± 100 |
| 4h | 120 ± 14 | 250 ± 15 | 300 ± 40 | 240 ± 38 | 780 ± 54 |
| 4i | 390 ± 20 | 1100 ± 100 | 920 ± 91 | 770 ± 15 | 1400 ± 120 |
| 5 | 14 ± 1 | 10 ± 8 | 18 ± 1 | 20 ± 2 | 14 ± 1 |
| 2a | 430 ± 40 | 280 ± 16 | 140 ± 20 | 87 ± 22 | ND |
| CA-4 | 2.8 ± 1.1 | 42 ± 6.0 | 16 ± 1.4 | 1.9 ± 1.6 | 1.9 ± 1.6 |
[a]
Compound concentration required to inhibit tumor cell proliferation by 50%; data are expressed as the mean ± SE from the dose–response curves of at least three independent experiments; ND: not determined.